Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284453 | 0.88 | THRA (0.39) | HTR2AIDH1ACACBCYP3A4ACSL1 | |
| SCHEMBL4281489 | 0.87 | ACACB (0.36) | HTR2AIDH1ACACBCYP3A4MAOB | |
| SCHEMBL4279412 | 0.85 | MAPT (0.43) | IDH1MAOBMAOAALDH1A1 | |
| SCHEMBL4291912 | 0.85 | NFKB1 (0.42) | IDH1CYP3A4MAOBALDH1A1 | |
| SCHEMBL4288111 | 0.84 | IDH1 (0.38) | IDH1CYP3A4NAAAALDH1A1 | |
| SCHEMBL4288478 | 0.84 | CYP3A4 (0.45) | HTR2AACACBCYP3A4ACSL1NAAA | |
| SCHEMBL4286495 | 0.82 | IDH1 (0.41) | IDH1CYP3A4MAOBALDH1A1 | |
| SCHEMBL4286864 | 0.82 | IDH1 (0.41) | IDH1CYP3A4MAOBALDH1A1 | |
| SCHEMBL4285320 | 0.82 | POLB (0.44) | HTR2AIDH1MAOBMAOAALDH1A1 | |
| SCHEMBL4279693 | 0.81 | SLC5A1 (0.45) | IDH1ACACBMAOBNAAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | HTR2A 910/4885PTGS1 2443/4885PTGS2 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.